Skip to Content

MabCampath

Active Substance: alemtuzumab
Common Name: alemtuzumab
ATC Code: L01XC04
Marketing Authorisation Holder: Genzyme Europe B.V.
Active Substance: alemtuzumab
Status: Withdrawn
Authorisation Date: 2001-07-06
Therapeutic Area: Leukemia, Lymphocytic, Chronic, B-Cell
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate.

The marketing authorisation for MabCampath has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide